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The early detection of breast cancer is the best means to minimise disease-related mortality. Current screening techniques
have limited sensitivity and speciﬁcity. Breast nipple aspirate ﬂuid can be obtained noninvasively and contains proteins secreted
from ductal and lobular epithelia. Nipple aspirate ﬂuid proteins are breast speciﬁc and generally more concentrated than
corresponding blood levels. Proteomic analysis of 1 ml of diluted nipple aspirate ﬂuid over a 5–40 kDa range from 20 subjects
with breast cancer and 13 with nondiseased breasts identiﬁed ﬁve differentially expressed proteins. The most sensitive and
speciﬁc proteins were 6500 and 15940 Da, found in 75–84% of samples from women with cancer but in only 0–9% of
samples from normal women. These ﬁndings suggest that (1) differential expression of nipple aspirate ﬂuid proteins exists
between women with normal and diseased breasts, and (2) analysis of these proteins may predict the presence of breast
cancer.
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Standard screening for breast cancer involves physical examination
and mammography. These tools alert the physician to the presence
of a mass which is palpated and/or an abnormality which is visua-
lised. Treatment of breast cancer requires a morphologic diagnosis
characterised by visual changes in the nuclei in a cytologic or histo-
logic preparation of breast cells. In order to obtain the cells for
review by the pathologist, a diagnostic needle, core, or surgical
biopsy must be performed. These procedures are painful, the needle
and core biopsies are subject to sampling error, and only approxi-
mately 15–20% of the procedures detect malignancy (Watson et
al, 1999). Non- and minimally invasive procedures are presently
under review to detect breast cancer without submitting the subject
to an invasive diagnostic procedure. These procedures include
nipple aspiration, ductal lavage, and ductoscopy. Of these, only
nipple aspiration is totally noninvasive and requires a device with
minimal cost. In addition, only nipple aspiration provides concen-
trated secreted proteins undiluted with irrigation ﬂuid which is
required to perform ductal lavage and ductoscopy.
While cytologic and histologic evaluation are the gold standards
to detect breast cancer, recent advances in comprehensive molecu-
lar technologies allow the simultaneous analysis of multiple protein
expression targets. Two-dimensional polyacrylamide gel electro-
phoresis (2D-PAGE) and mass spectrometry have been used to
perform proteomic analysis of human breast epithelium for
comparison of cancer with normal breast (Czerwenka et al, 2001;
Paweletz et al, 2001), changes in protein synthesis after growth
factor induction (Vercoutter-Edouart et al, 2001), to detect new
breast cancer markers and proteins involved in cell pathways such
as signalling and the humoural response to antigens (Hondermarck
et al, 2001; Le Naour et al, 2001), and to develop a breast cancer
protein expression map database (Harris et al, 2002). Technologies
in development include protein chips using antibodies or aptamers
(short strings of DNA or RNA that bind with high afﬁnity to speci-
ﬁc target proteins) as capture molecules (Abbot, 2002).
A wide array of proteins are secreted into and highly concen-
trated in NAF and have been associated with breast cancer. We
hypothesised that the proteome wide analysis of NAF using
surface-enhanced laser desorption/ionization time of ﬂight-mass
spectrometry (SELDI-TOF) would identify one or more proteins
differentially expressed in women with breast cancer compared to
subjects without disease. The SELDI technique can be performed
with 1 ml of NAF, can detect components in the high femtomole
range, and the chip surface which allows the rapid evaluation of
8–24 samples has high throughput potential. Candidate breast
cancer biomarkers can be identiﬁed using SELDI with a rapid
immunoassay.
MATERIALS AND METHODS
After informed consent of an Institutional Review Board approved
protocol, NAF was collected using a modiﬁed breast pump (Sauter
et al, 1996) and coded so that all analyses were blinded. Specimens
were collected from women 35–81 years old scheduled to undergo
surgery for a suspected malignancy in the aspirated breast, as well
as from women without evidence of disease (Table 1). NAF was
diluted with Tris buffer to a concentration of 3.6 mg total protein
ml
71 Tris buffer. Proteome analysis with the SELDI PBSII system
(Ciphergen Biosystems, Fremont, CA, USA) was carried out on
three chips, normal phase (NP), hydrophobic (H4) and anion
exchange (SAX), using 1 ml of NAF. The chromatographic surfaces
of these ProteinChips allow the capture of generic proteins (NP),
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binding by anion exchange (SAX). NP and SAX chips were washed
ﬁrst with binding buffer containing detergent, then with detergent-
free buffer and water to remove nonspeciﬁc proteins. H4 chips
were loaded with 10% acetonitrile, then washed with this solvent
and water.
RESULTS
A representative ProteinChip SELDI MS analysis of NAF demon-
strates discrete peaks (Figure 1) at 6500 and 8000 Da from three
of four tumour bearing women which are not present or are
present at a reduced level in NAF from women with normal breast
tissue. We considered a protein expressed if the value assigned by
SELDI software had a signal-to-noise ratio 53:1. Protein peaks
from different samples were judged similar if the values in Da were
within 0.05% of each other. The ﬁgure also demonstrates a distinct
peak at 15940 Da in four out of four NAF samples from women
with breast cancer that is not observed in NAF from normal
subjects. Two larger proteins (a broad-based peak centered at
28100 Da and a peak at 31770, not shown) were also identiﬁed
in a high percentage of women with breast cancer but were absent
or present at a reduced level in NAF from normal women.
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Table 1 Patient demographics
Menopausal status Cancer No cancer
Pre- 9 10
Post- 11 3
Race
White 17 9
Nonwhite 3 4
Age
Median 52 44
Range 33–81 29–55
Ever pregnant
Yes 17 8
No 3 5
Median age (years) at 1st pregnancy 27 21
Ever used birth control pills
Yes 11 8
No 9 5
Ever used hormone replacement medications
Yes 6 1
No 14 12
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Figure 1 SELDI-TOF proﬁle (5–20 kDa) from eight NAF samples. The top four lanes are from subjects with breast cancer.
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women with and without cancer and odds ratios (ORs) with
95% conﬁdence intervals (CIs) are listed in Table 2. Because
of the small sample size, all estimates and P-values were
computed using exact methods (LogXact 4.0, Cytel Software
Corporation, Cambridge, MA, USA). Protein peaks at
15940 Da in all chips, at 8000 Da in the H4 and NP chips, at
6500 Da in the H4 and SAX chips, and at 28100 Da in the
NP chip were expressed signiﬁcantly more often in NAF samples
from subjects with breast cancer than from normal subjects
(Table 2). For each chip, maximum sensitivity and speciﬁcity
were achieved with the single protein peak: 15940 Da in the
H4 and NP chips, and 6500 Da in the SAX chip (Table 2,
bolded rows). These proteins were separately evaluated in multi-
variable logistic regression models controlling for age, race, past
pregnancy, and past use of oral contraceptives. The adjusted
odds ratios were: 29.2 (95% CI: 4.44 to ?, P50.001) for the
15940 Da protein using the H4 chip, 27.3 (95% CI: 3.93 to
?, P50.001) for the 6500 Da using the SAX chip, and 18.7
(95% CI: 2.52 to 6.36, P=0.002) for the 15940 Da using the
NP chip.
DISCUSSION
While both RNA and protein proﬁling can be applied to tissue
samples, analysis of body ﬂuids such as NAF is restricted to
proteomics due to their low cellularity (Kennedy, 2001). Proteo-
mic analysis of breast tissue has been reported using 2-D PAGE
(Hondermarck et al, 2001). Although sensitive and powerful, 2-
D PAGE is a labour intensive and low throughput method, has
the drawback of selecting against proteins which are extremely
acidic or basic, and there is a detection bias toward highly
abundant proteins. The recently developed SELDI technique
(Davies et al, 1999) allows for the rapid proﬁling of extracts
from cells, tissues, and physiological ﬂuids and can screen large
numbers of samples in a clinical setting by differential protein
capture according to chemical (ionic, hydrophobic, hydrophilic
or metal ion afﬁnity) surfaces on a protein chip.
Of the differentially expressed proteins identiﬁed using SELDI
MS, the 6500 and 15940 Da proteins are particularly striking since
they were detected in a high percentage of subjects with breast
cancer but in no one (6500 using the SAX chip and the 15940
using the NP chip) or very few women without breast cancer.
The identity of the 6500 Da protein is not known but may repre-
sent epithelin, while the 8000 Da peak may by mammaglobin.
Mammaglobin has been reported to be a breast cancer marker
(Watson et al, 1999). The identity of the 15940 protein has not
been determined. The 31770 peak is most likely a dimer of the
15940 protein.
The identity of the 28100 Da peak may represent one or more
members of the kallikrein family. A recent report using SELDI MS
(Watkins et al, 2001) analysed the sera of 46 women with breast
cancer and 23 controls. A 28.3 kDa protein was found in 100% of
women with invasive and 80% with non-invasive breast cancer,
respectively, but in only 4% of women without disease. This
protein may correspond to the 28.1 kDa peak we observed in
NAF, although conﬁrmation is required. The putative breast
cancer marker proteins that we have detected in this study may
represent different isoforms of the candidate proteins or other
known proteins. We are currently characterising the MS peaks
identiﬁed in this study to determine their protein signature. We
have also instituted a prospective analysis of NAF using SELDI-
TOF to conﬁrm the differential expression of these proteins in
breast cancer vs normal breast, and plan to use a bioinformatics
approach to identify the proteomic patterns in NAF that distin-
guish cancer from normal (Petricoin et al, 2002).
In conclusion, proteomic analysis of NAF from subjects with
and without breast cancer identiﬁed ﬁve differentially expressed
proteins. The most sensitive and speciﬁc proteins were 6500 and
15940 Da, found in 75–84% of samples from women with cancer
but in only 0–9% of samples from normal women. While current
tools to detect breast cancer are widely available and clinically
effective, they have limited sensitivity and speciﬁcity. Analysis of
NAF proteins secreted from the breast epithelium may increase
our ability to detect breast cancer at its earliest stages when used
in combination with mammography and physical examination.
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Table 2 Protein expression proﬁle in NAF (by size) obtained from normal women and from
women with breast cancer, using three different SELDI ProteinChips (NP,SAX, and H4)
Protein
Positive
in tumour
Positive
in normal
Chip peak (sensitivity) (1-speciﬁcity) OR (95% CI) P-value
NP
6500 Da 12/19 63% 3/11 27% 4.33 (0.72. ?) 0.128
8000 Da 15/19 79% 1/11 9% 31.73 (3.11, ?) 50.001
15 940 Da 16/19 84% 1/11 9% 43.10 (4.01, ?) 50.001
28 100 Da 8/19 42% 0/11 0% 9.61 (1.37, ?) 0.026
31 770 Da 6/19 32% 0/11 0% 6.16 (0.77, ?) 0.091
SAX
6500 Da 15/20 75% 0/12 0% 54.67 (7.26, ?) 50.001
8000 Da 4/20 20% 0/13 0% 2.91 (0.24, 160) 0.661
15 940 Da 11/20 55% 0/13 0% 19.04 (2.61, ?) 0.002
28 100 Da 8/20 40% 2/13 15% 3.53 (0.53, 41.3) 0.264
31 770 Da 0/20 0% 0/13 0% n/e
H4
6500 Da 13/20 65% 2/13 15% 9.44 (1.46, 111) 0.013
8000 Da 12/20 60% 2/13 15% 7.71 (1.20, 90.0) 0.027
15 940 Da 16/20 80% 0/13 0% 72.02 (9.32, ?) 50.001
28 100 Da 5/19 26% 0/12 0% 5.63 (0.69, ?) 0.116
31 770 Da 1/19 5% 0/12 0% 0.68 (0.02, ?) 1.000
OR: odds ratio. CI: conﬁdence interval. n/e: not estimable.
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